Merck Balance Sheet Health
Financial Health criteria checks 4/6
Merck has a total shareholder equity of $44.6B and total debt of $38.1B, which brings its debt-to-equity ratio to 85.6%. Its total assets and total liabilities are $117.5B and $73.0B respectively. Merck's EBIT is $18.9B making its interest coverage ratio 20.7. It has cash and short-term investments of $14.6B.
Key information
85.6%
Debt to equity ratio
US$38.13b
Debt
| Interest coverage ratio | 20.7x |
| Cash | US$14.59b |
| Equity | US$44.56b |
| Total liabilities | US$72.97b |
| Total assets | US$117.53b |
Recent financial health updates
Recent updates
Merck: A Low-Hanging Fruit To Pick
Dec 23Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Dec 20
Merck: Buy Opportunity Backed By Growth
Dec 17Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.81
Dec 02The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
Nov 15Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Nov 14Merck: An Undervalued Dividend Machine
Nov 07Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Oct 25Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)
Oct 15Merck Is At Support And Should Go Higher (Technical Analysis)
Oct 07Merck Appears Ready To Return To June Highs (Technical Analysis)
Sep 14Financial Position Analysis
Short Term Liabilities: MRK's short term assets ($40.4B) exceed its short term liabilities ($29.6B).
Long Term Liabilities: MRK's short term assets ($40.4B) do not cover its long term liabilities ($43.4B).
Debt to Equity History and Analysis
Debt Level: MRK's net debt to equity ratio (52.8%) is considered high.
Reducing Debt: MRK's debt to equity ratio has reduced from 96.9% to 85.6% over the past 5 years.
Debt Coverage: MRK's debt is well covered by operating cash flow (47.9%).
Interest Coverage: MRK's interest payments on its debt are well covered by EBIT (20.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 07:30 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Merck & Co., Inc. is covered by 61 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |
| Ishan Majumdar | Baptista Research |